Back to results
US 10,307,461 B2Granted
Method of preventing polycystic kidney disease and PKD animal model with exogenous neutrophil gelatinase-associated lipocalin
AssigneeNational Taiwan Normal University
InventorsHsiu-Mei Hsieh, Yi-Ren Wang, Si-Tse Jiang, Wen-Yih Jeng, Yuan-Yow Chiou
Life of this patent
Estimating the term…
Abstract
Disclosed is a method of treating or preventing polycystic kidney disease (PKD) by administration of neutrophil geleatinase-associated lipocalin (Ngal) protein. Also, a transgenic non-human animal model is established to investigate the effect of overexpression of exogenous Ngal on PKD progression.
Claims5
A method of preventing polycystic kidney disease (PKD), comprising:
- administering an effective amount of neutrophil gelatinase-associated lipocalin (NGAL) to a subject in need, wherein preventing PKD is statistically significantly improving survival and lifespan of a patient through at least four of the following pathophysiological mechanisms or features:
- retarding renal cyst growth, reducing renal cyst volume and kidney/body weight, reducing renal interstitial fibrosis, reducing hypoxia in the interstitial compartment of kidney, increasing apoptosis of cystic epithelial cells and decreasing proliferation of cystic epithelial cells in the kidney;
- wherein the PKD is autosomal dominant polycystic kidney disease (ADPKD), and administering the effective amount of neutrophil gelatinase-associated lipocalin (NGAL) is before statistically significant ischemic injury.
Dependencies are inferred from the claim text.